Skip to main content

Menu

BNF September 2022 Update

This update contains 9 significant changes, 6 new monographs, and 1 deleted preparation.

Significant Changes:

  • Controlled drugs and drug dependence: updated guidance on the prescribing of drugs associated with dependence and withdrawal.
  • Cystic fibrosis transmembrane conductance regulator modulators: update to hepatic impairment advice (see example in ivacaftor).
  • Dexmedetomidine: clinical trial finds increased risk of mortality in intensive care unit (ICU) patients aged 65 years or younger [MHRA/CHM advice].
  • Epilepsy: updated guidance on management.
  • Hydrocortisone: addition of children’s dosing for adrenal crisis.
  • Immunisation schedule: updated guidance for immunisation against influenza.
  • Influenza vaccine: updated guidance for immunisation.
  • Tezacaftor with ivacaftor and elexacaftor: name change to ivacaftor with tezacaftor and elexacaftor.
  • Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure [MHRA/CHM advice].

New Monographs:

  • Aklief® [trifarotene].
  • Brukinsa® [zanubrutinib].
  • Magnesium citrate.
  • NovoThirteen® [factor XIII A-subunit (recombinant)].
  • Padcev® [enfortumab vedotin].
  • Palforzia® [peanut protein].

Deleted Preparation:

  • Codeine phosphate solution for injection.

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699